MCID: NSS002
MIFTS: 47

Neisseria Meningitidis Infection

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Neisseria Meningitidis Infection

MalaCards integrated aliases for Neisseria Meningitidis Infection:

Name: Neisseria Meningitidis Infection 52
Meningococcal Disease 52 3
Meningococcal Infections 71
Meningococcal Diseases 54

Classifications:



External Ids:

UMLS 71 C0025303

Summaries for Neisseria Meningitidis Infection

CDC : 3 Meningococcal disease refers to any illness caused by bacteria called Neisseria meningitidis, also known as meningococcus [muh-ning-goh-KOK-us]. These illnesses are often severe and can be deadly. They include infections of the lining of the brain and spinal cord (meningitis) and bloodstream infections (bacteremia or septicemia). These bacteria spread through the exchange of respiratory and throat secretions like spit (e.g., by living in close quarters, kissing). Doctors treat meningococcal disease with antibiotics, but quick medical attention is extremely important. Keeping up to date with recommended vaccines is the best defense against meningococcal disease.

MalaCards based summary : Neisseria Meningitidis Infection, also known as meningococcal disease, is related to meningococcal meningitis and meningococcemia, and has symptoms including fever and pruritus. An important gene associated with Neisseria Meningitidis Infection is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Phenytoin and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and b cells, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Neisseria Meningitidis Infection

Diseases related to Neisseria Meningitidis Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 meningococcal meningitis 31.2 TLR4 TLR2 MBL2 DHPS CFP C3
2 meningococcemia 30.7 MBL2 IL1RN CFP
3 mannose-binding lectin deficiency 30.6 MBL2 CFP
4 complement component 5 deficiency 30.1 CFP CD46 C3
5 epiglottitis 30.0 OMP LACTB
6 haemophilus influenzae 29.9 TLR2 OMP LACTB
7 complement deficiency 29.9 MBL2 CFP CD46 C3
8 complement component 3 deficiency 29.8 MBL2 CFP CD46 C3
9 glomerulonephritis 29.7 MBL2 CFP CD46 C3
10 membranoproliferative glomerulonephritis 29.6 CFP CD46 C3
11 toxic shock syndrome 29.6 TLR4 TLR2 IL1RN IL1R1
12 neutropenia 29.5 TLR4 MBL2 LACTB IL1RN
13 typhoid fever 29.5 TLR4 OMP IL1R1
14 bacterial sepsis 29.3 TLR4 TLR2 IL1RN
15 autoimmune disease 29.0 MBL2 IL1RN IL1R1 FCGR2A C3
16 osteomyelitis 29.0 TLR4 TLR2 IL1RN
17 immune deficiency disease 29.0 TLR2 MBL2 CFP CD46
18 common cold 29.0 TLR4 TLR2 IL1R1
19 endocarditis 28.8 TLR2 LACTB FCGR2A
20 bacterial pneumonia 28.8 TLR4 TLR2 LACTB
21 bacterial meningitis 28.8 TLR4 TLR2 MBL2 LACTB CFP C3
22 measles 28.7 TLR4 TLR2 MSN CD46
23 bacterial infectious disease 28.3 TLR4 TLR2 MBL2 IL1RN IL1R1 FCGR2A
24 thrombocytopenia 28.1 TLR4 TLR2 MBL2 IL1RN FCGR2A CD46
25 otitis media 28.0 TLR4 TLR2 MBL2 LACTB IL1RN C3
26 meningitis 27.9 TLR4 TLR2 MBL2 LACTB FCGR2A CFP
27 pneumonia 27.6 TLR4 TLR2 MBL2 LACTB IL1RN DHPS
28 systemic lupus erythematosus 26.9 TLR4 TLR2 MBL2 IL1RN IL1R1 FCGR2A
29 complement component 8 deficiency 11.8
30 meningococcal infection 10.7
31 exanthem 10.6
32 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
33 diffuse glomerulonephritis 10.4 CFP C3
34 complement component 6 deficiency 10.3
35 purpura 10.3
36 disseminated intravascular coagulation 10.3
37 complement factor i deficiency 10.3 CFP C3
38 ocular motor apraxia 10.3
39 purpura fulminans 10.2
40 septic arthritis 10.2
41 pouchitis 10.2 TLR4 IL1RN
42 atypical hemolytic uremic syndrome with complement gene abnormality 10.2 CD46 C3
43 iga glomerulonephritis 10.2 MBL2 CFP C3
44 influenza 10.2
45 vasculitis 10.2
46 cytokine deficiency 10.2
47 hypersensitivity reaction type iii disease 10.2 FCGR2A CFP C3
48 tetanus 10.2
49 diarrhea 10.2
50 myocarditis 10.2

Graphical network of the top 20 diseases related to Neisseria Meningitidis Infection:



Diseases related to Neisseria Meningitidis Infection

Symptoms & Phenotypes for Neisseria Meningitidis Infection

UMLS symptoms related to Neisseria Meningitidis Infection:


fever, pruritus

MGI Mouse Phenotypes related to Neisseria Meningitidis Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 C3 CD46 CFP IL1R1 IL1RN LACTB
2 hematopoietic system MP:0005397 10.02 C3 DHPS EZR FCGR2A IL1R1 IL1RN
3 homeostasis/metabolism MP:0005376 10 C3 CFP DHPS IL1R1 IL1RN LACTB
4 immune system MP:0005387 9.9 C3 CFP DHPS EZR FCGR2A IL1R1
5 normal MP:0002873 9.56 C3 CFP DHPS IL1R1 MSN OMP
6 skeleton MP:0005390 9.23 C3 CFP FCGR2A IL1R1 IL1RN MBL2

Drugs & Therapeutics for Neisseria Meningitidis Infection

Drugs for Neisseria Meningitidis Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Zidovudine Approved Phase 4 30516-87-1 35370
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Complement Factor H Phase 4
12
protease inhibitors Phase 4
13 HIV Protease Inhibitors Phase 4
14 BB 1101 Phase 4
15 Sodium Channel Blockers Phase 4
16 Immunologic Factors Phase 4
17 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
18 Anti-Retroviral Agents Phase 4
19 Anti-HIV Agents Phase 4
20 Reverse Transcriptase Inhibitors Phase 4
21 Vitamin B Complex Phase 4
22 Folate Phase 4
23 Folic Acid Antagonists Phase 4
24 Dermatologic Agents Phase 4
25 Vitamin B9 Phase 4
26 penicillins Phase 4
27 Gentamicins Phase 4
28 beta-Lactams Phase 4
29 Lactams Phase 4
30 Immunoglobulins Phase 4
31 Antibodies Phase 4
32 Neuromuscular Blocking Agents Phase 4
33
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
34
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
37
Sertraline Approved Phase 3 79617-96-2 68617
38
Vancomycin Approved Phase 3 1404-90-6 14969 441141
39
Sulfamethoxazole Approved Phase 3 723-46-6 5329
40
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
41
Glycerol Approved, Investigational Phase 3 56-81-5 753
42
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
45
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
46
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
47
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
48
Ethambutol Approved Phase 3 74-55-5 3279 14052
49
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
50
Isoniazid Approved, Investigational Phase 3 54-85-3 3767

Interventional clinical trials:

(show top 50) (show all 402)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
3 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
4 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
5 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
6 A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea. Completed NCT01766206 Phase 4
7 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
8 A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine Completed NCT01823536 Phase 4
9 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
10 Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information. Completed NCT00290329 Phase 4
11 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
12 An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs Completed NCT01129518 Phase 4
13 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
14 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
15 A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age Completed NCT00310635 Phase 4
16 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
17 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
18 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
19 South Australian Meningococcal B Vaccine Herd Immunity Study Completed NCT03089086 Phase 4
20 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
21 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
22 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
23 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
24 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
25 A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea Completed NCT02446691 Phase 4
26 Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. Completed NCT01745679 Phase 4 Ceftriaxone treatment
27 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
28 A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
29 A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
30 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
31 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
32 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
33 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
34 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
35 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
36 A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants Completed NCT00581035 Phase 4
37 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
38 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
39 A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB) Completed NCT02080559 Phase 4
40 An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi Completed NCT01247909 Phase 4 Ceftriaxone v penicillin and gentamicin
41 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
42 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola. Completed NCT01540838 Phase 4 Infusion with paracetamol;Bolus without paracetamol
43 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
44 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
45 Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age Completed NCT01430689 Phase 4
46 The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger Completed NCT01119482 Phase 4
47 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
48 A Randomized, Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada; a Canadian Immunization Research Network (CIRN) Study. Recruiting NCT03694405 Phase 4
49 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Recruiting NCT03682939 Phase 4
50 A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults Recruiting NCT03493919 Phase 4

Search NIH Clinical Center for Neisseria Meningitidis Infection

Genetic Tests for Neisseria Meningitidis Infection

Anatomical Context for Neisseria Meningitidis Infection

MalaCards organs/tissues related to Neisseria Meningitidis Infection:

40
Brain, Testes, B Cells, Spinal Cord, Colon, Monocytes, Endothelial

Publications for Neisseria Meningitidis Infection

Articles related to Neisseria Meningitidis Infection:

(show top 50) (show all 3905)
# Title Authors PMID Year
1
A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. 54 61
19067670 2009
2
Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. 54 61
17692067 2007
3
Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. 61 54
17484222 2007
4
Antigenic shift and increased incidence of meningococcal disease. 54 61
16586364 2006
5
Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. 61 54
16395111 2006
6
Human-like immune responses in CD46 transgenic mice. 61 54
15972677 2005
7
Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. 54 61
15569696 2005
8
Relevance of genetically determined host factors to the prognosis of meningococcal disease. 61 54
15243816 2004
9
Association between familial deficiency of mannose-binding lectin and mutations in the corresponding gene and promoter region. 61 54
15242964 2004
10
Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? 61 54
14647192 2003
11
Clinical potential of mannose-binding lectin-replacement therapy. 61 54
12887301 2003
12
CD46 in meningococcal disease. 54 61
12869763 2003
13
Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. 54 61
12730365 2003
14
Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. 61 54
12667023 2003
15
Lps2 and signal transduction in sepsis: at the intersection of host responses to bacteria and viruses. 54 61
14620135 2003
16
A case of familial meningococcal disease due to deficiency in mannose-binding lectin (MBL). 61 54
12916805 2003
17
Variable number tandem repeat polymorphism of the interleukin-1 receptor antagonist gene in meningococcal disease. 61 54
12145738 2002
18
Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. 54 61
11812402 2002
19
False penicillin resistance in Neisseria meningitidis following direct susceptibility tests from blood cultures. 61 54
11684730 2001
20
Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. 61 54
11598838 2001
21
A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. 54 61
11494169 2001
22
[Role of host response during severe bacterial infection]. 61 54
11582914 2001
23
[Immunology in the clinical practice. XXVIII. Susceptibility to meningococcal disease due to a familial deficiency of mannose-binding lectin]. 54 61
11072514 2000
24
Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies. 61 54
10909851 2000
25
The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. 61 54
10792385 2000
26
Genetic dissection of the molecular pathogenesis of severe infection. 61 54
10786964 2000
27
Properdin deficiency and meningococcal disease--identifying those most at risk. 61 54
10540177 1999
28
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 54 61
10509505 1999
29
Mannose-binding lectin and meningococcal disease. 54 61
10440333 1999
30
Mannose-binding lectin and meningococcal disease. 54 61
10440334 1999
31
Mannose-binding lectin and meningococcal disease. 54 61
10440335 1999
32
Mannose-binding lectin and meningococcal disease. 61 54
10440336 1999
33
Mannose-binding lectin and meningococcal disease. 61 54
10440337 1999
34
Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. 61 54
10199352 1999
35
Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. 61 54
9844044 1998
36
Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. 54 61
9798027 1998
37
Clonal distribution of invasive Neisseria meningitidis isolates from the Norwegian county of Telemark, 1987 to 1995. 54 61
9705404 1998
38
Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations. 61 54
9710744 1998
39
Carrier detection by microsatellite haplotyping in 10 properdin type 1-deficient families. 54 61
8911864 1996
40
Molecular characterization of properdin deficiency type III: dysfunction produced by a single point mutation in exon 9 of the structural gene causing a tyrosine to aspartic acid interchange. 61 54
8871668 1996
41
Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. 61 54
7562997 1995
42
Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. 61 54
8530058 1995
43
[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis]. 61 54
7501623 1995
44
Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. 54 61
8132350 1994
45
Low prevalence of complement deficiencies among patients with meningococcal disease in Norway. 54 61
8469932 1993
46
A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease. 54 61
8469930 1993
47
Carrier detection in families with properdin deficiency by microsatellite haplotyping. 54 61
8423238 1993
48
Inherited complement deficiency states: implications for immunity and immunological disease. 54 61
2147105 1990
49
Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. 54 61
2397612 1990
50
Complement and immunoglobulin studies in 15 cases of chronic meningococcemia: properdin deficiency and hypoimmunoglobulinemia. 54 61
2320962 1990

Variations for Neisseria Meningitidis Infection

Expression for Neisseria Meningitidis Infection

Search GEO for disease gene expression data for Neisseria Meningitidis Infection.

Pathways for Neisseria Meningitidis Infection

Pathways related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TLR4 TLR2 MBL2 IL1RN IL1R1 FCGR2A
2
Show member pathways
12.51 TLR4 TLR2 IL1RN IL1R1
3 12.05 TLR4 TLR2 MSN EZR
4 11.95 TLR4 IL1R1 FCGR2A EZR
5
Show member pathways
11.9 MBL2 CD46 C3
6
Show member pathways
11.9 TLR4 TLR2 FCGR2A C3
7 11.89 MBL2 CD46 C3
8
Show member pathways
11.81 TLR4 TLR2 IL1R1
9 11.81 TLR4 TLR2 FCGR2A C3
10 11.78 TLR4 IL1R1 FCGR2A
11 11.69 TLR4 TLR2 IL1R1
12
Show member pathways
11.66 MBL2 CFP CD46 C3
13 11.65 MBL2 FCGR2A C3
14
Show member pathways
11.61 TLR4 TLR2 IL1R1
15
Show member pathways
11.54 MBL2 CFP C3
16 11.34 TLR4 TLR2 C3
17 11.2 TLR4 TLR2 MBL2 FCGR2A C3
18 11.19 TLR4 TLR2 FCGR2A C3

GO Terms for Neisseria Meningitidis Infection

Cellular components related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.73 TLR4 TLR2 ROM1 IL1R1 FCGR2A CD46
2 microvillus membrane GO:0031528 9.32 MSN EZR
3 cell surface GO:0009986 9.17 TLR4 TLR2 MSN MBL2 IL1R1 CD46
4 uropod GO:0001931 9.16 MSN EZR
5 invadopodium GO:0071437 8.96 MSN EZR

Biological processes related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 TLR4 TLR2 MSN EZR CD46
2 innate immune response GO:0045087 9.85 TLR4 TLR2 MBL2 CFP CD46 C3
3 inflammatory response GO:0006954 9.83 TLR4 TLR2 IL1RN IL1R1 C3
4 regulation of complement activation GO:0030449 9.77 CFP CD46 C3
5 complement activation GO:0006956 9.73 MBL2 CFP C3
6 regulation of cell size GO:0008361 9.63 MSN EZR
7 positive regulation of chemokine production GO:0032722 9.62 TLR4 TLR2
8 establishment of endothelial barrier GO:0061028 9.62 MSN EZR
9 establishment of epithelial cell apical/basal polarity GO:0045198 9.61 MSN EZR
10 positive regulation of interleukin-8 secretion GO:2000484 9.61 TLR4 TLR2
11 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.59 TLR4 TLR2
12 positive regulation of cellular protein catabolic process GO:1903364 9.58 MSN EZR
13 complement activation, alternative pathway GO:0006957 9.58 CFP C3
14 I-kappaB phosphorylation GO:0007252 9.57 TLR4 TLR2
15 cellular response to lipoteichoic acid GO:0071223 9.55 TLR4 TLR2
16 gland morphogenesis GO:0022612 9.54 MSN EZR
17 positive regulation of early endosome to late endosome transport GO:2000643 9.52 MSN EZR
18 positive regulation of protein localization to early endosome GO:1902966 9.51 MSN EZR
19 membrane to membrane docking GO:0022614 9.48 MSN EZR
20 regulation of organelle assembly GO:1902115 9.46 MSN EZR
21 immune response GO:0006955 9.43 TLR4 TLR2 IL1RN IL1R1 CFP C3
22 interleukin-10 production GO:0032613 9.4 TLR2 CD46
23 positive regulation of interleukin-10 production GO:0032733 9.33 TLR4 TLR2 CD46
24 positive regulation of matrix metallopeptidase secretion GO:1904466 9.32 TLR4 TLR2
25 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.26 TLR4 TLR2
26 immune system process GO:0002376 9.17 TLR4 TLR2 MBL2 FCGR2A CFP CD46

Molecular functions related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 TLR4 MSN MBL2 C3
2 lipopolysaccharide receptor activity GO:0001875 9.16 TLR4 TLR2
3 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.13 TLR4 TLR2 IL1R1
4 NAD(P)+ nucleosidase activity GO:0050135 8.8 TLR4 TLR2 IL1R1

Sources for Neisseria Meningitidis Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....